# Tesamorelin Research: The Pivotal Trials, Walked in Order

> Tesamorelin research timeline: the 2007 NEJM trial (VAT -15.2%), the 52-week program, the 2014 JAMA liver-fat RCT, and the 2026 meta-analysis. Every figure cited.

From the 2007 NEJM pivotal RCT to a 2026 meta-analysis, each study is a dated node on the board. Here is what each one actually measured.

## The short version

This is the tesamorelin research record, walked in order. The story runs from a 2007 trial that first showed deep belly fat shrinking, through a year-long follow-up, a liver-fat study, and a 2026 review pooling five trials. The through-line is consistent: in people with HIV-associated fat redistribution, tesamorelin reduced visceral fat (deep abdominal fat) and raised IGF-1 (the liver's growth signal). Almost all of this evidence sits inside one population — HIV patients — which is exactly the boundary the FDA approval respects. Each finding below is cited to its study.

## What the pivotal trials measured

The foundation is the 2007 New England Journal of Medicine trial: a 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation. Tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2%, while placebo increased it by 5.0%; triglycerides fell by 50 mg/dL (versus +9 mg/dL on placebo) and IGF-1 rose 81.0% [1]. An earlier 12-week dose-ranging study had already shown the dose-dependence — IGF-I up +48% at 1 mg and +65% at 2 mg, with trunk fat reduced and glucose unchanged [8].

These **tesamorelin results** proved durable. The 52-week program (273 on tesamorelin, 137 on placebo) sustained visceral-fat reduction at -18% (P<0.001 versus baseline), with glucose changes over the year that were not clinically significant [2]. One caveat sits beside the result: visceral fat reaccumulated upon discontinuation, so the benefit depended on continued dosing [2].

## The liver-fat finding

In 2014, a JAMA RCT extended the work to the liver. Among 50 antiretroviral-treated HIV adults (28 tesamorelin, 22 placebo), tesamorelin produced a visceral-fat treatment effect of -42 cm2 (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) over six months [3]. This is the most-cited evidence that the visceral-fat mechanism carries through to hepatic fat — though tesamorelin remains investigational, not approved, for fatty-liver disease outside its HIV indication [5].

## Fat quality, not just quantity

A 2021 analysis published in AIDS looked past how much fat was lost to the quality of the fat that remained. Over 26 weeks, tesamorelin increased CT-measured fat density — visceral +6.2 HU versus +0.3 placebo, subcutaneous +4.0 HU versus +0.3, both P<0.0001 — indicating improved fat-tissue quality independent of changes in fat quantity [11]. It is a reminder that the trial endpoints evolved over time, from simple volume to tissue character.

## Who responded — predictors and subgroups

Pooled and subgroup analyses sharpened the picture of *who* responds. In a pooled analysis of two Phase 3 RCTs (543 tesamorelin versus 263 placebo), the odds of reducing visceral fat below 140 cm2 were 3.9-fold greater with tesamorelin (95% CI 2.03-7.44); baseline metabolic syndrome, triglycerides above 1.7 mmol/L, and white race predicted response, with no predictors identifiable at 3 months [12]. A 2023 post-hoc analysis found the visceral-fat and waist-circumference benefit was comparable in patients with and without dorsocervical fat accumulation (no significant subgroup difference, P=0.657) [13].

## The evidence at scale: reviews and meta-analysis

Synthesis confirms the single trials. A systematic review of 10 placebo-controlled trials (1,511 patients) of growth-hormone-axis treatments — including tesamorelin — found significant visceral-fat reduction (weighted mean difference -25.2 cm2) and increased lean body mass, with arthralgias and oedema as the significant adverse effects [10]. The 2026 meta-analysis of five RCTs reported a pooled visceral-fat reduction of -27.71 cm2 (95% CI -38.37 to -17.06), trunk fat -1.18 kg, hepatic fat fraction -4.28%, and lean body mass +1.42 kg — all P<0.001, without serious adverse events [15]. Reviews from 2009 and 2011 frame the development rationale and the favorable HIV-lipodystrophy safety profile [7][9].

## The boundary of the evidence

The most important thing the research record says is where it *stops*. Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy; generalizability to non-HIV populations is mechanistically plausible but not established by large RCTs [4]. The only non-HIV human data is the mechanistic healthy-men study, and no large general-population fat-loss RCT has been completed [4]. The FDA approval (2010) is confined to HIV-associated lipodystrophy [5]. Reading the literature honestly means reading that boundary as part of the result, not a footnote to it.

---

The tesamorelin literature walked node by node — each trial figure, the GHRH-to-IGF-1 cascade, and the FDA-HIV-only scope chalked up where the studies put them and cited to source; a teaching board, not a clinic, a vendor, or a prescription.